萬泰生物(603392.SH)生產的新型冠狀病毒抗原檢測試劑盒獲得德國BfArM批准
格隆匯4月18日丨萬泰生物(603392.SH)公佈,公司生產的新型冠狀病毒(2019-nCoV)抗原檢測試劑盒(膠體金法)(英文名稱WANTAI SARS-CoV-2 AgRapid Test (Colloidal Gold),德文名稱WANTAI SARS-CoV-2 Ag Schnelltest(Kolloidales Gold)),於近日獲得德國BfArM批准。
該產品之前獲得歐盟CE認證(專業人員使用),可在歐盟國家和認可歐盟CE認證的國家銷售。此次獲得德國BfArM批准後,可在德國市場銷售。該產品可滿足非專業人員自檢使用需求,性能穩定,靈敏度和特異性高,對公司國際業務拓展具有積極的作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.